AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

TSE:AUPAurinia Pharmaceuticals Stock Price, Forecast & News

C$21.18
-0.71 (-3.24 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
C$21.07
Now: C$21.18
C$21.93
50-Day Range
C$20.31
MA: C$22.89
C$25.74
52-Week Range
C$4.70
Now: C$21.18
C$28.59
Volume122,365 shs
Average Volume170,737 shs
Market CapitalizationC$2.38 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.69 out of 5 stars


Industry, Sector and Symbol

Industry Technical & System Software
Sub-IndustryN/A
SectorComputer and Technology
CUSIPN/A
CIKN/A
Phone+1-250-7084272

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$318,000.00
Cash FlowC$2.45 per share
Book ValueC$2.34 per share

Profitability

Miscellaneous

Employees39
Market CapC$2.38 billion
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive AUP News and Ratings via Email

Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter.

Aurinia Pharmaceuticals (TSE:AUP) Frequently Asked Questions

How has Aurinia Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Aurinia Pharmaceuticals' stock was trading at C$19.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AUP stock has increased by 9.3% and is now trading at C$21.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals.

When is Aurinia Pharmaceuticals' next earnings date?

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aurinia Pharmaceuticals.

How were Aurinia Pharmaceuticals' earnings last quarter?

Aurinia Pharmaceuticals Inc (TSE:AUP) released its quarterly earnings results on Thursday, March, 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.12. The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.05 million. View Aurinia Pharmaceuticals' earnings history.

Has Aurinia Pharmaceuticals been receiving favorable news coverage?

News coverage about AUP stock has trended extremely positive recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Aurinia Pharmaceuticals earned a coverage optimism score of 4.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View the latest news aboutAurinia Pharmaceuticals.

Who are some of Aurinia Pharmaceuticals' key competitors?

What other stocks do shareholders of Aurinia Pharmaceuticals own?

Who are Aurinia Pharmaceuticals' key executives?

Aurinia Pharmaceuticals' management team includes the following people:
  • Dr. Richard M. Glickman, Founder, Chairman, Pres & CEO (Age 61)
  • Mr. Michael R. Martin, Co-Founder & COO
  • Mr. Dennis Bourgeault CPA, C.A., CFO & Sec.
  • Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
  • Dr. Neil Solomons M.D., Chief Medical Officer

What is Aurinia Pharmaceuticals' stock symbol?

Aurinia Pharmaceuticals trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."

How do I buy shares of Aurinia Pharmaceuticals?

Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Aurinia Pharmaceuticals' stock price today?

One share of AUP stock can currently be purchased for approximately C$21.18.

How big of a company is Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals has a market capitalization of C$2.38 billion and generates C$318,000.00 in revenue each year. Aurinia Pharmaceuticals employs 39 workers across the globe.

What is Aurinia Pharmaceuticals' official website?

The official website for Aurinia Pharmaceuticals is www.auriniapharma.com.

How can I contact Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals' mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.